Wendela L. de Ranitz-Greven

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

H. Nathoe, L. Kappelle, G. D. de Borst, 2021, Cardiovascular Diabetology.

Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin

L. B. E. A. Hoeks, H. D. de Valk, D. Biesma, 2014, BMC Research Notes.

Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy.

J. Beulens, G. Visser, H. D. de Valk, 2012, Diabetes technology & therapeutics.

Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.

H. D. de Valk, Wendela L. de Ranitz-Greven, Dieuwke C Bos, 2011, Diabetes technology & therapeutics.

Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus.

G. Visser, H. D. de Valk, D. Biesma, 2012, Diabetes technology & therapeutics.

The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry

F. Zwartkruis, J. Westerink, Wendela L. de Ranitz-Greven, 2022, Orphanet Journal of Rare Diseases.